Table 3.

Rates of Complete Hematologic Response, Major Cytogenetic Response (All Studies), and Major Molecular Response (CA180-013 Study Only) in Patients Treated With Dasatinib After Loss of Response to Prior Imatinib

	Patients, n/N (%)
Variable	Group 1: Loss of MCyR on Imatinib	Group 2: Loss of MCyR and CHR on Imatinib	Group 3: Loss of CHR on Imatinib Without Prior MCyR
CHR: All patients	139/151 (92)	28/33 (85)	98/109 (90)
MCyR: All patients	123/151 (81)	21/33 (64)	38/109 (35)
CCyR
All patients	108/151 (72)	14/33 (42)	28/109 (26)
CCyR data by dosing schedule
70 mg BID population	67/89 (75)	10/25 (40)	20/78 (26)
100 mg QD population	21/28 (75)	1/1 (100)	1/9 (11)
Other regimens, 50 mg BID or 140 mg QD	20/34 (59)	3/7 (43)	7/22 (32)
CCyR data by study
Study CA180-013, 70 mg BID	36/47 (77)	6/17 (35)	13/50 (26)
Study CA180-017, 70 mg BID	12/19 (63)	1/2 (50)	5/20 (25)
Study CA180-034
100 mg QD	21/28 (75)	1/1 (100)	1/9 (11)
50 mg BID	11/17 (65)	1/2 (50)	2/10 (20)
140 mg QD	9/17 (53)	2/5 (40)	5/12 (42)
70 mg BID	19/23 (83)	3/6 (50)	2/8 (25)
MMR: Study CA180-013, 70 mg BID*	28/47 (60)	5/17 (29)	13/50 (26)

MCyR indicates major cytogenetic response; CHR, complete hematologic response; CCyR, complete cytogenetic response; BID, twice daily; QD, once daily; MMR, major molecular response.

^*In all assessed patients.